- Home
- QFIN vs CDTX Comparison
QFIN vs CDTX Comparison
Compare QFIN & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QFIN
- CDTX
- Stock Information
- Founded
- QFIN 2016
- CDTX 2012
- Country
- QFIN China
- CDTX United States
- Employees
- QFIN N/A
- CDTX N/A
- Industry
- QFIN Finance: Consumer Services
- CDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- QFIN Finance
- CDTX Health Care
- Exchange
- QFIN Nasdaq
- CDTX Nasdaq
- Market Cap
- QFIN 3.1B
- CDTX 2.8B
- IPO Year
- QFIN 2018
- CDTX 2015
- Fundamental
- Price
- QFIN $18.04
- CDTX $219.75
- Analyst Decision
- QFIN Strong Buy
- CDTX Buy
- Analyst Count
- QFIN 3
- CDTX 13
- Target Price
- QFIN $37.07
- CDTX $119.44
- AVG Volume (30 Days)
- QFIN 2.5M
- CDTX 2.2M
- Earning Date
- QFIN 11-18-2025
- CDTX 11-06-2025
- Dividend Yield
- QFIN 8.37%
- CDTX N/A
- EPS Growth
- QFIN 40.93
- CDTX N/A
- EPS
- QFIN 6.93
- CDTX N/A
- Revenue
- QFIN $2,752,357,572.00
- CDTX N/A
- Revenue This Year
- QFIN $17.10
- CDTX N/A
- Revenue Next Year
- QFIN $6.28
- CDTX N/A
- P/E Ratio
- QFIN $2.78
- CDTX N/A
- Revenue Growth
- QFIN 14.06
- CDTX N/A
- 52 Week Low
- QFIN $18.01
- CDTX $15.02
- 52 Week High
- QFIN $48.94
- CDTX $220.32
- Technical
- Relative Strength Index (RSI)
- QFIN 26.63
- CDTX 89.35
- Support Level
- QFIN $21.59
- CDTX $102.46
- Resistance Level
- QFIN $22.88
- CDTX $218.85
- Average True Range (ATR)
- QFIN 1.01
- CDTX 4.30
- MACD
- QFIN -0.22
- CDTX 12.80
- Stochastic Oscillator
- QFIN 0.84
- CDTX 99.47
About QFIN Qifu Technology Inc.
Qfin Holdings Inc Formerly Qifu Technology Inc is a Credit-Tech platform in China. It provides credit services more accessible and personalized to consumers and SMEs through Credit-Tech services to financial institutions, whereby it deploys its technology solutions to help financial institutions identify the diversified needs of consumers and SMEs, effectively access prospective borrowers that are creditworthy through multi-channels, enhance credit assessment on prospective borrowers, and manage credit risks and improve collection strategies and efficiency, among others.
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.